Teclison
Mike Bond brings over 25+ years of biotechnology R&D experience in analytical method development/validation, protein characterization, and CMC activities. At Janssen/Johnson & Johnson, Mike served as both Director of Analytics and Director of Large Molecule Pharma Development and Manufacturing. Under his leadership, he successfully led the commercialization from Phase I of multiple products, including monoclonal antibody therapeutics Stelara and Simponi. He brings decades of experience in multiple BLA/NDA filings as well. Mike Bond received his Ph.D. in Biochemistry from Florida State University and completed his Postdoctoral Research at Harvard Medical School.
This person is not in any offices
Teclison
Teclison was founded with the vision of assembling leading scientists, advisors, and other leaders with significant pharmaceutical expertise to develop groundbreaking therapies for cancer. The company specializes in the development of innovative cancer medicines which induce tumor necrosis and enhance anti-tumor immunity for long-term cancer remission.